Today: 20 May 2026
Browse Category

NASDAQ:ARQT 30 December 2025 - 12 January 2026

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics shares fell 8.7% to $25.76 Monday after the company set a 2026 net product sales target of $455–$470 million for its ZORYVE franchise. The company reported $99.2 million in net product revenue last quarter and ended September with $191.4 million in cash. Arcutis plans to expand its sales team by 20% and expects key clinical trial data in early 2026. The stock hit a session low of $25.51.
12 January 2026
··
Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis Biotherapeutics shares fell 5.3% to $28.29 Friday after an early surge, tracking a shift in rate expectations following a soft U.S. jobs report. Broader biotech indexes rose. Investors are watching for Arcutis’ next earnings on Feb. 24 and an FDA decision on ZORYVE for children by June 29. The Fed’s late-January meeting remains a key focus for traders.
9 January 2026
···
Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day

Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day

Arcutis Biotherapeutics shares closed up 3.4% at $29.04 in the final trading session of the year. A Form 144 filing showed Chief Medical Officer Patrick Burnett plans to sell 1,697 shares after acquiring them through restricted stock vesting. U.S. stock markets are closed Thursday for New Year’s Day and reopen Friday. The stock’s move contrasted with a broader market pullback.
1 January 2026
·

Stock Market Today

  • Euronext Q1 2026 Sees Record Trading Volumes and 15.3% Revenue Growth
    May 20, 2026, 5:43 AM EDT. Euronext reported a record Q1 2026 with cash equity trading and clearing revenue up 30.8% to €123 million, driven by high market volatility and the full contribution from Euronext Athens. Total underlying revenue rose 15.3% to €528.5 million, marking the exchange's eighth consecutive quarter of double-digit growth. Average daily cash equity transaction value in April reached €16.4 billion, with a 64.1% market share. Commodities trading revenue climbed 13.9%, while FX revenue grew 5.8%. ETF trading surged 84% since September 2025, boosted by the launch of mini ETF options. Adjusted EBITDA rose 16.7% to €343.2 million, with net income up 17.7%. Euronext declared a €3.18 dividend per share, reflecting a 50% payout, payable in May.

Latest articles

Co-Diagnostics Stock Surges — Then $3 Million Financing Puts The Rally To The Test

Co-Diagnostics Stock Surges — Then $3 Million Financing Puts The Rally To The Test

20 May 2026
New York, May 20, 2026, 05:08 EDT Co-Diagnostics shares face an early test on Wednesday after the diagnostic-test developer announced a $3 million private placement hours after its stock closed up 43.8% at $1.97 on Tuesday. Extended-hours trading showed the shares down 13.3% at $1.71 before the regular Nasdaq session. (MarketBeat) The timing matters. Co-Diagnostics had rallied after saying it had completed a strategy to develop an assay, or diagnostic test, for the Bundibugyo virus behind a fast-moving Ebola outbreak in Democratic Republic of Congo and Uganda. The late financing then shifted attention to dilution and cash needs. The company
Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

20 May 2026
Micron Technology shares rose 2.5% Tuesday to $698.74, lifting its market value near $798 billion as the Nasdaq fell. Analysts cited tight memory supply and strong DRAM and NAND pricing. A planned strike by 48,000 Samsung workers Thursday could disrupt global memory supply, potentially raising prices. Micron recently sampled 256GB DDR5 server modules to partners.
Wall Street Puts $150 Target on Intel in AI Push

Wall Street Puts $150 Target on Intel in AI Push

20 May 2026
Intel shares rose 2.43% to $110.80 on Tuesday, ending a five-day losing streak. The stock rebounded as analysts raised price targets, citing demand for AI server CPUs. Intel traded between $102.40 and $113.07 during the session. The Nasdaq Composite fell 0.84%, with Nvidia and AMD also down.
Go toTop